{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:00:55Z","timestamp":1791644455233,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2026.02.238","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:05:43Z","timestamp":1772121943000},"page":"1434-1444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC"],"prefix":"10.1016","volume":"125","author":[{"given":"Peter S.N.","family":"van Rossum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-7075","authenticated-orcid":false,"given":"Pim J.J.","family":"Damen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cortiula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhe","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Famke L.","family":"Schneiders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wijsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.02.238_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdj117","article-title":"Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients","volume":"17","author":"Aup\u00e9rin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0003","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0004","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an Antagonistic Anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2023.02.013","article-title":"Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations","volume":"184","author":"Cortiula","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0006","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: State of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0007","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: Durvalumab after chemoradiotherapy in unresectable stage III EGFR-Mutant NSCLC: A post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0008","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: A systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2018.09.010","article-title":"The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors","volume":"103","author":"Pike","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"154","author":"Friedes","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0011","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2018.12.002","article-title":"The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy","volume":"133","author":"Deng","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0014","article-title":"Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC","volume":"3","author":"Jing","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non\u2013small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110019","article-title":"Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy","volume":"190","author":"Cortiula","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: Analysis of 3 phase 1\/2 trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0016","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.prro.2019.07.010","article-title":"Prediction of severe lymphopenia during chemoradiation therapy for esophageal cancer: Development and validation of a pretreatment nomogram","volume":"10","author":"van Rossum","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0017","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2023.08.058","article-title":"Severe lymphopenia during chemoradiation therapy for esophageal cancer: Comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy","volume":"118","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0019","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1448658","article-title":"Updates on radiation-induced lymphopenia","volume":"14","author":"Damen","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0022","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3389\/fonc.2019.01488","article-title":"Prognosis and risk factors of radiation-induced lymphopenia in early-stage lung cancer treated with stereotactic body radiation therapy","volume":"9","author":"Zhao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2021.01.034","article-title":"Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0024","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2020.09.002","article-title":"Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes","volume":"154","author":"Xie","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0026","first-page":"15","article-title":"Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy","volume":"22","author":"Abravan","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0027","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/jcm12051833","article-title":"Immunotherapy in elderly patients affected by non-small cell lung cancer: A narrative review","volume":"12","author":"Montrone","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0028","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/jcm8071014","article-title":"Baseline absolute lymphocyte count and ECOG performance score are associated with survival in advanced non-small cell lung cancer undergoing PD-1\/PD-L1 blockade","volume":"8","author":"Huemer","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0029","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0031","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1287555","article-title":"Influence of treatment-related lymphopenia on the efficacy of immune checkpoint inhibitors in lung cancer: A meta-analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109934","article-title":"Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"189","author":"Yang","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijrobp.2023.11.037","article-title":"The role of thoracic vertebral body dosimetry in minimizing acute hematologic toxicities of patients with non-small cell lung cancer receiving lung radiation therapy and immunotherapy","volume":"119","author":"Ma","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1278723","article-title":"Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models","volume":"13","author":"van Rossum","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0036","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1134\/S1990519X2204006X","article-title":"Lymphopenia and mechanisms of T-cell regeneration","volume":"16","author":"Saidakova","year":"2022","journal-title":"Cell Tissue Biol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004512","article-title":"T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma","volume":"10","author":"Wang","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0038","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27357","article-title":"Sustained CD4+T cell-driven lymphopenia without a compensatory IL-7\/IL-15 response among high-grade glioma patients treated with radiation and temozolomide","volume":"3","author":"Ellsworth","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0039","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: The rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.adro.2018.09.004","article-title":"A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer","volume":"4","author":"Routman","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0042","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0043","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.19.02503","article-title":"Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0044","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14338\/IJPT-20-00086","article-title":"Radiation-induced lymphopenia risks of photon versus proton therapy for esophageal cancer patients","volume":"8","author":"Ebrahimi","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1088\/0031-9155\/54\/12\/N01","article-title":"Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept","volume":"54","author":"Raaymakers","year":"2009","journal-title":"Med Biol Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0046","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.prro.2022.11.003","article-title":"Preliminary evaluation of PTV margins for online adaptive radiation therapy of the prostatic fossa","volume":"13","author":"Morgan","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0047","doi-asserted-by":"crossref","first-page":"245ra93","DOI":"10.1126\/scitranslmed.3008973","article-title":"Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice","volume":"6","author":"Favaudon","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0048","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"MacKall","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijrobp.2026.02.238_bib0049","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-015-1841-y","article-title":"Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas","volume":"124","author":"Campian","year":"2015","journal-title":"J Neuro-Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:25:06Z","timestamp":1784276706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626004281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0360301626004281"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.238","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}